Brian Buntz

A3 President Jeff Burnstein describes core automation policy needs for the U.S. to secure to regain international standing in the field.

LinkedInEmailShare The relentless demand for faster, smaller and more efficient electronic devices is finally pushing existing silicon technology to its physical limits. Decades of phenomenal innovation have largely delivered the prophesy of Moore’s Law, which predicts that the number of transistors that can be crammed onto a silicon chip should double every two years, but there are growing signs that it is becoming too difficult to maintain that pace of progress. Chipmakers like Intel and TSMC are introducing radically new device architectures to continue the trend towards increased feature sets on smaller geometries, while a technology roadmap produced by imec, the microelectronics research center in Leuven, Belgium, suggests that new electronic materials will start to displace silicon in mass-market devices from the mid-2030s as they emerge from research and become commercialized.

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.

LinkedInEmailShare Yes, questions remain whether AI chipmaker NVIDIA can keep up the momentum in 2025. NVIDIA’s upcoming Blackwell AI chips have run into thermal problems when integrated into server racks designed to house up to 72 units. This matter has led the company to request multiple redesigns of these racks to mitigate the thermal challenges.

Industrial and commercial sectors often measure innovation by market capitalization and R&D spending, but these metrics fail to capture the full picture. Tech companies dominate market headlines with AI product launches and chip releases — and our own ranking of most innovative firms of 2024. In addition, tech firms currently hold the top market cap…

Industrial and commercial sectors often measure innovation by market capitalization and R&D spending, but these metrics fail to capture the full picture. Tech companies dominate market headlines with AI product launches and chip releases — and our own ranking of most innovative firms of 2024. In addition, tech firms currently hold the top market cap positions (NVIDIA at $3.56T, Apple at $3.43T, Microsoft at $3.05T). Tech giants, too, are among the top spenders in R&D in raw dollars with Alphabet spending $12.447 billion in the third quarter while Meta invested $11.177 billion.

| The digital pathology firm PathAI has released PathExplore Fibrosis 1, an AI-based tool that analyzes fibrosis and collagen structures from H&E-stained whole-slide tissue images.

| In 2024, we saw the expanded use of synthetic data and natural language processing transform drug discovery and development.

LinkedInEmailShare Imagine a future where needing a new heart means you become your own donor. “It’s going to be your cells, your design—an exact replica of your heart, only made healthy,” said Steven Levine, Ph.D., senior director of virtual human modeling at Dassault Systèmes, in a recent interview.

LinkedInEmailShare In a week of significant AI industry developments, Amazon doubled down on its Anthropic investment with an additional $4 billion, while NVIDIA reported another quarter of remarkable growth with sales hitting $35.1 billion. Meanwhile, a debate emerged at the Cerebral Valley AI Summit about whether AI development is hitting a scaling wall, with industry leaders like Anthropic’s Dario Amodei and Scale AI’s Alexandr Wang taking opposing positions. In biotech, the Human Cell Atlas Consortium reported major progress in mapping human cells, while Converge Bio secured $5.5 million to build what it calls the “everything store for biotech LLMs.”